SBIR Phase I: Improving The Bioavailability of the Natural Antioxidant Astaxanthin from Haematococcus Pluvialis

SBIR 第一阶段：提高雨生红球藻天然抗氧化剂虾青素的生物利用度

• 批准号: 0320032
• 负责人: Fan Lu
• 金额: $ 9.99万
• 依托单位: Algaen Corporation
• 依托单位国家: 美国
• 项目类别: Standard Grant
• 财政年份: 2003
• 资助国家: 美国
• 起止时间: 2003-07-01 至 2004-03-31
• 项目状态: 已结题
• 来源: https://www.nsf.gov/awardsearch/showAward?AWD_ID=0320032&HistoricalAwards=false
• 关键词: SBIR; Phase; Improving; Bioavailability; Natural

This Small Business Innovation Research (SBIR) Phase I project proposes to improve the bioavailability of astaxanthin from the green algae, Haematococcus pluvialis, through molecular genetic manipulation of the organism. Natural astaxanthin is a potent bioactive antioxidant and offers tremendous potential for use in nutraceutical, pharmaceutical, aquaculture, and poultry industries. The green alga, Haematococcus pluvialis, is the richest known natural source of astaxanthin. One major constraint in the Haematococcus production system, however, is that astaxanthin-rich cells (cysts) possess thick cell walls that hinder astaxanthin extraction and subsequent bioavailability for humans and cultured animals. Chemical and physical cell disruption processes account for a major cost of the production, yet introduce the risk of oxidation of astaxanthin. In this Phase I project, certain features of Haematococcus will be genetically altered so as to facilitate fast and efficient extraction and digestion of cell-bound astaxanthin. The immediate commercial application of this project will be in the nutraceutical and aquaculture markets.

该小企业创新研究 (SBIR) 第一阶段项目提出通过对绿藻雨生红球藻进行分子遗传操作，提高该生物体中虾青素的生物利用度。天然虾青素是一种有效的生物活性抗氧化剂，在营养保健品、制药、水产养殖和家禽工业中具有巨大的应用潜力。绿藻雨生红球藻是已知最丰富的虾青素天然来源。然而，红球藻生产系统的一个主要限制是富含虾青素的细胞（囊肿）具有厚的细胞壁，阻碍了虾青素的提取以及随后对人类和培养动物的生物利用度。化学和物理细胞破碎过程占生产成本的主要部分，但也带来了虾青素氧化的风险。在该第一阶段项目中，将对红球藻的某些特征进行基因改变，以促进细胞结合虾青素的快速有效提取和消化。该项目的直接商业应用将是在营养保健品和水产养殖市场。